Mitochondrial abnormalities in the putamen in Parkinson's disease dyskinesia.

Naydenov AV, Vassoler F, Luksik AS, Kaczmarska J, Konradi C
Acta Neuropathol. 2010 120 (5): 623-31

PMID: 20740286 · PMCID: PMC2955799 · DOI:10.1007/s00401-010-0740-8

Prolonged treatment of Parkinson's disease (PD) with levodopa leads to disabling side effects collectively referred to as 'dyskinesias'. We hypothesized that bioenergetic function in the putamen might play a crucial role in the development of dyskinesias. To test this hypothesis, we used post mortem samples of the human putamen and applied real time-PCR approaches and gene expression microarrays. We found that mitochondrial DNA (mtDNA) levels are decreased in patients who have developed dyskinesias, and mtDNA damage is concomitantly increased. These pathologies were not observed in PD subjects without signs of dyskinesias. The group of nuclear mRNA transcripts coding for the proteins of the mitochondrial electron transfer chain was decreased in patients with dyskinesias to a larger extent than in patients who had not developed dyskinesias. To examine whether dopamine fluctuations affect mtDNA levels in dopaminoceptive neurons, rat striatal neurons in culture were repeatedly exposed to levodopa, dopamine or their metabolites. MtDNA levels were reduced after treatment with dopamine, but not after treatment with dopamine metabolites. Levodopa led to an increase in mtDNA levels. We conclude that mitochondrial susceptibility in the putamen plays a role in the development of dyskinesias.

MeSH Terms (18)

Animals Antiparkinson Agents Chromatography, High Pressure Liquid DNA, Mitochondrial Dopamine Dyskinesia, Drug-Induced Humans Levodopa Male Mitochondria Neurons Oligonucleotide Array Sequence Analysis Parkinson Disease Putamen Rats Reverse Transcriptase Polymerase Chain Reaction RNA RNA, Mitochondrial

Connections (1)

This publication is referenced by other Labnodes entities: